Breaking News Instant updates and real-time market news.

2022-07-01 08:05:28 BAC Bank of America $31.16 / -0.67 (-2.10%) , C Citi $46.02 / -1.07 (-2.27%) … 08:05 07/01/22 07/01 08:05 07/01/22 08:05	Oppenheimer says U.S. financial institutions 'dramatically undervalued' In a sector note on U.S. financial institutions, Oppenheimer analyst Chris Kotowski said that while it is reasonable to expect some noise in upcoming Q2 results, he expects "in-line fundamental trends" and has only made generally modest revisions to his firm's 2023 estimates. Kotowski continues to believe the group is "dramatically undervalued relative to the market at a 51% relative P/E" and continues to recommend Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), Jefferies (JEF), JPMorgan (JPM), Morgan Stanley (MS), SVB Financial (SIVB), and U.S. Bancorp (USB), all of which are Outperform rated. Kotowski also has Perform ratings on PNC Financial Services (PNC) and Wells Fargo (WFC). BAC Bank of America $31.16 / -0.67 (-2.10%) C Citi $46.02 / -1.07 (-2.27%) GS Goldman Sachs $297.73 / -5.87 (-1.93%) JEF Jefferies Financial Group $27.62 / -0.305 (-1.09%) JPM JPMorgan $112.67 / -2.61 (-2.26%) MS Morgan Stanley $76.13 / -1.98 (-2.53%) SIVB SVB Financial $395.30 / -7.55 (-1.87%) USB U.S. Bancorp $46.06 / -0.04 (-0.09%) PNC PNC Financial $157.96 / +0.32 (+0.20%) WFC Wells Fargo $39.19 / -0.51 (-1.28%)	14 Jul 14 Jul 15 Jul 15 Jul 15 Jul 15 Jul 18 Jul 18 Jul 19 Sep 10 Aug

2022-07-01 08:05:28

BAC

Bank of America

$31.16 / -0.67 (-2.10%)

, C

Citi

$46.02 / -1.07 (-2.27%)

… 08:05

07/01/22

07/01

08:05

07/01/22

08:05

Oppenheimer says U.S. financial institutions 'dramatically undervalued'

In a sector note on U.S. financial institutions, Oppenheimer analyst Chris Kotowski said that while it is reasonable to expect some noise in upcoming Q2 results, he expects "in-line fundamental trends" and has only made generally modest revisions to his firm's 2023 estimates. Kotowski continues to believe the group is "dramatically undervalued relative to the market at a 51% relative P/E" and continues to recommend Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), Jefferies (JEF), JPMorgan (JPM), Morgan Stanley (MS), SVB Financial (SIVB), and U.S. Bancorp (USB), all of which are Outperform rated. Kotowski also has Perform ratings on PNC Financial Services (PNC) and Wells Fargo (WFC).

BAC

Bank of America

$31.16 / -0.67 (-2.10%)

Citi

$46.02 / -1.07 (-2.27%)

Goldman Sachs

$297.73 / -5.87 (-1.93%)

JEF

Jefferies Financial Group

$27.62 / -0.305 (-1.09%)

JPM

JPMorgan

$112.67 / -2.61 (-2.26%)

Morgan Stanley

$76.13 / -1.98 (-2.53%)

SIVB

SVB Financial

$395.30 / -7.55 (-1.87%)

USB

U.S. Bancorp

$46.06 / -0.04 (-0.09%)

PNC

PNC Financial

$157.96 / +0.32 (+0.20%)

WFC

Wells Fargo

$39.19 / -0.51 (-1.28%)

14
Jul
14
Jul
15
Jul
15
Jul
15
Jul
15
Jul
18
Jul
18
Jul
19
Sep

10
Aug

OTHER BREAKING NEWS FROM THE FLY

Earnings	BIO-key reports Q2 EP (21c) vs. (15c) last year » 08:00 08/12/22 08/12 08:00 08/12/22 08:00 BKYI BIO-key $2.15 / +0.115 (+5.65%) Reports Q2 revenue $1.9M … Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Earnings Events BKYI BIO-key $2.15 / +0.115 (+5.65%) 07/21/22 Long Island University selects BIO-key's PortalGuard IAM platform 07/18/22 Darksteel Technologies selects PortalGuard IAM 07/14/22 BIO-key to showcase PortalGuard IAM at NACo Annual Conference 06/21/22 BIO-key showcases biometric cybersecurity solutions at MSP Expo Florida BKYI BIO-key $2.15 / +0.115 (+5.65%) 05/16/22 BIO-key sees 2022 revenue $10M-$13M 05/16/22 BIO-key reports Q1 EPS (12c) vs. (11c) last year 03/29/22 BIO-key sees 2022 revenue $10M-$13M, one est. $15M 03/29/22 BIO-key reports Q4 EPS (26c) vs. (18c) last year 10:00 Today BIO-key - BKYI
Options	Apple put buyer realizes 14% same-day gains » 08:00 08/12/22 08/12 08:00 08/12/22 08:00 AAPL Apple $168.49 / -0.73 (-0.43%) Notable profits for the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options AAPL Apple $168.49 / -0.73 (-0.43%) 08/03/22 Microsoft says Teams now optimized for Mac computers 07/28/22 Apple says 'constantly surveilling' the market for potential acquisitions 07/28/22 Apple expects Q4 revenue to accelerate y/y 07/28/22 Apple says response to iPhone 13 'continues to be strong' AAPL Apple $168.49 / -0.73 (-0.43%) 08/11/22 Craig-Hallum Enovix price target raised to $25 from $20 at Craig-Hallum 08/11/22 Loop Capital Loop Capital has 'stronger conviction' in Enovix after 'customer milestones' 08/10/22 Bernstein Apple Services performance fundamentally better than believed, says Bernstein 08/08/22 B. Riley B. Riley thinks Globalstar's mystery satellite capacity customer is Apple AAPL Apple $168.49 / -0.73 (-0.43%) 07/28/22 Apple reports Q3 EPS $1.20, consensus $1.16 07/28/22 Notable companies reporting after market close 04/28/22 Apple says y/y Q3 revenue growth to be impacted by COVID 04/28/22 Apple reports Q2 EPS $1.52, consensus $1.43 AAPL Apple $168.49 / -0.73 (-0.43%) 08/11/22 Apple assemblers seen making 220M iPhones for 2022, Bloomberg says 08/10/22 Apple signs agreement with 'Suave' maker Futuro Studios, Bloomberg reports 08/10/22 TSMC receives sub-7nm chip orders from Qualcomm, DigiTimes reports 08/10/22 Taiwan wants Foxconn to unwind stake in Tsinghua, FT reports AAPL Apple $168.49 / -0.73 (-0.43%) 08/10/22 #SocialStocks: Musk sells Tesla shares should he lose legal battle with Twitter 08/10/22 What Wall Street is saying about Disney ahead of earnings 08/09/22 What You Missed On Wall Street This Morning 08/08/22 What You Missed On Wall Street This Morning AAPL Apple $168.49 / -0.73 (-0.43%) 08/11/22 Notable open interest changes for August 11th 08/10/22 Notable open interest changes for August 10th 08/09/22 Notable open interest changes for August 9th 08/08/22 Notable open interest changes for August 8th
Recommendations	Roblox price target raised to $52 from $45 at Deutsche Bank » 07:56 08/12/22 08/12 07:56 08/12/22 07:56 RBLX Roblox $49.55 / +1.52 (+3.16%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options RBLX Roblox $49.55 / +1.52 (+3.16%) 08/10/22 Cathie Wood's ARK Investment bought 191K shares of Roblox today 08/09/22 Roblox drops 13% to $41.29 after Q2 results miss estimates 08/09/22 Roblox reports Q2 bookings $639.9M, down 4% y/y 08/02/22 U.S. video game consumer spending fell 13% y/y in Q2, says NPD RBLX Roblox $49.55 / +1.52 (+3.16%) 08/11/22 Wedbush Roblox price target raised to $34 from $28 at Wedbush 08/10/22 Morgan Stanley Roblox price target raised to $32 from $25 at Morgan Stanley 08/08/22 Truist Roblox price target raised to $45 from $29 at Truist 08/01/22 MKM Partners Roblox price target raised to $40 from $28 at MKM Partners RBLX Roblox $49.55 / +1.52 (+3.16%) 08/09/22 Roblox reports Q2 EPS (30c), consensus (23c) 08/09/22 Notable companies reporting after market close 05/10/22 Roblox reports Q1 EPS (27c), consensus (21c) 05/10/22 Notable companies reporting after market close RBLX Roblox $49.55 / +1.52 (+3.16%) 04/06/22 Meta plans to introduce virtual coins for the metaverse, FT reports RBLX Roblox $49.55 / +1.52 (+3.16%) 08/10/22 What You Missed On Wall Street On Wednesday 08/10/22 What You Missed On Wall Street This Morning 08/10/22 Fly Intel: Pre-market Movers 08/09/22 Fly Intel: After-Hours Movers RBLX Roblox $49.55 / +1.52 (+3.16%) 08/10/22 Roblox put buyer realizes 18% same-day gains 08/09/22 Roblox options imply 15.6% move in share price post-earnings 07/08/22 Unusually active option classes on open July 8th 07/06/22 Unusually active option classes on open July 6th
Recommendations	Oppenheimer encouraged as 'key initiatives taking hold' at CarMax » 07:56 08/12/22 08/12 07:56 08/12/22 07:56 KMX CarMax $101.64 / +1.71 (+1.71%) Oppenheimer analyst Brian… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options KMX CarMax $101.64 / +1.71 (+1.71%) 06/24/22 CarMax plans to open ten new locations in FY23 06/24/22 CarMax sold 427,257 units in Q1, down 5.5% from the prior year quarter 05/16/22 Tepper's Appaloosa buys two casinos in Q1, exits T-Mobile and GM 04/12/22 CarMax drops 5% to $98.05 after Q4 earnings miss estimates KMX CarMax $101.64 / +1.71 (+1.71%) 07/14/22 Morgan Stanley CarMax price target lowered to $124 from $140 at Morgan Stanley 06/27/22 RBC Capital CarMax price target raised to $108 from $104 at RBC Capital 06/27/22 Wedbush CarMax price target raised to $105 from $90 at Wedbush 06/27/22 Baird CarMax valuation attractive for patient investors, says Baird KMX CarMax $101.64 / +1.71 (+1.71%) 06/24/22 CarMax reports Q1 EPS $1.56, consensus $1.49 06/23/22 Notable companies reporting before tomorrow's open 06/23/22 Notable companies reporting before tomorrow's open 04/12/22 CarMax reports Q4 EPS 98c, consensus $1.25 KMX CarMax $101.64 / +1.71 (+1.71%) 02/26/22 Deere among quality companies doing business mostly in the U.S., Barron's says KMX CarMax $101.64 / +1.71 (+1.71%) 06/24/22 What You Missed On Wall Street On Friday 06/24/22 What You Missed On Wall Street This Morning 05/02/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/13/22 What You Missed On Wall Street On Wednesday 09/29/22 CarMax - KMX KMX CarMax $101.64 / +1.71 (+1.71%) 04/12/22 Unusually active option classes on open April 12th
Recommendations	GeoPark price target lowered to $22 from $24 at Canaccord » 07:54 08/12/22 08/12 07:54 08/12/22 07:54 GPRK GeoPark $12.50 / +0.55 (+4.60%) Canaccord lowered the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Earnings GPRK GeoPark $12.50 / +0.55 (+4.60%) 08/10/22 GeoPark raises quarterly dividend by 50% to 12.7c per share 06/21/22 GeoPark provides business activity update 06/21/22 GeoPark falls -8.9% 06/21/22 GeoPark falls -7.4% GPRK GeoPark $12.50 / +0.55 (+4.60%) 03/09/22 GeoPark reports Q4 adjusted EBITDA $87.1M vs. $56.0M last year
Recommendations	ForgeRock price target raised to $20 from $15 at Deutsche Bank » 07:54 08/12/22 08/12 07:54 08/12/22 07:54 FORG ForgeRock $22.24 / -1.13 (-4.84%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events FORG ForgeRock $22.24 / -1.13 (-4.84%) 08/11/22 ForgeRock reports Q2 ARR $201.6M, up 30% y/y 05/11/22 ForgeRock introduces ForgeRock Autonomous Access 03/02/22 ForgeRock falls -10.0% FORG ForgeRock $22.24 / -1.13 (-4.84%) 07:39 Today Cowen ForgeRock price target lowered to $25 from $28 at Cowen 07/13/22 Piper Sandler ForgeRock price target raised to $25 from $24 at Piper Sandler 06/22/22 JPMorgan ForgeRock price target lowered to $30 from $36 at JPMorgan 05/12/22 Deutsche Bank ForgeRock price target lowered to $15 from $16 at Deutsche Bank FORG ForgeRock $22.24 / -1.13 (-4.84%) 08/11/22 ForgeRock sees FY22 adjusted EPS (49c)-(44c), consensus (42c) 08/11/22 ForgeRock sees Q3 adjusted EPS (17c)-(13c), consensus (7c) 08/11/22 ForgeRock reports Q2 adjusted EPS (17c), consensus (21c) 05/11/22 ForgeRock cuts FY22 EPS view to (45c)-(41c) from (38c)-(34c), consensus (36c) 16 Sep FORG ForgeRock $22.24 / -1.13 (-4.84%) 08/11/22 Fly Intel: After-Hours Movers 02/26/22 Short Report: Avis Budget, VTEX short interest at multi-week highs 08/23/22 ForgeRock 08/28/22 ForgeRock
Recommendations	Privia Health price target raised to $51 from $36 at Guggenheim » 07:53 08/12/22 08/12 07:53 08/12/22 07:53 PRVA Privia Health $37.81 / +1.42 (+3.90%) Guggenheim analyst Sandy… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events PRVA Privia Health $37.81 / +1.42 (+3.90%) 03/31/22 Privia Health appoints Cocozza to board of directors 03/22/22 Privia Health CFO Jeff Sherman resigns PRVA Privia Health $37.81 / +1.42 (+3.90%) 07:49 Today Canaccord Privia Health price target raised to $45 from $40 at Canaccord 07:41 Today Cowen Privia Health price target raised to $44 from $35 at Cowen 07/14/22 Truist Privia Health price target raised to $40 from $36 at Truist 06/29/22 Canaccord Privia Health price target raised to $40 from $29 at Canaccord PRVA Privia Health $37.81 / +1.42 (+3.90%) 08/11/22 Privia Health sees 2022 revenue at high end of $1.225B-$1.3B 08/11/22 Privia Health reports Q2 adjusted EPS 13c vs. 9c last year. 05/12/22 Privia Health sees FY22 revenue at the mid to high end of $1.225B-$1.3B range 05/12/22 Privia Health reports Q1 adjusted EPS 12c, consensus (4c) 19 Nov PRVA Privia Health $37.81 / +1.42 (+3.90%) 05/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/22/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/20/22 Privia Health 09/21/22 Privia Health
Recommendations	2seventy Bio price target lowered to $28 from $42 at Canaccord » 07:51 08/12/22 08/12 07:51 08/12/22 07:51 TSVT 2seventy Bio $16.58 / -0.66 (-3.83%) Canaccord analyst John… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options TSVT 2seventy Bio $16.58 / -0.66 (-3.83%) 08/10/22 Bristol-Myers, 2seventy Bio: KarMMa-3 trial met primary endpoint 05/12/22 2seventy Bio sees $250M-$300M total U.S. commercial revenue in 2022 02/14/22 2seventy Bio appoints Steven Bernstein as CMO TSVT 2seventy Bio $16.58 / -0.66 (-3.83%) 07/20/22 Canaccord Canaccord starts Arcellx at Buy, sees 'best-in-class' potential 05/02/22 Goldman Sachs 2seventy Bio initiated with a Buy at Goldman Sachs 02/10/22 SVB Leerink SVB Leerink bullish on 2seventy Bio, initiates with an Outperform 02/10/22 SVB Leerink 2seventy Bio initiated with an Outperform at SVB Leerink TSVT 2seventy Bio $16.58 / -0.66 (-3.83%) 08/10/22 2seventy Bio reports Q2 EPS ($2.02), consensus ($2.08) 05/12/22 2seventy Bio reports Q1 EPS ($3.20), consensus ($2.05) 03/22/22 2seventy Bio reports Q4 EPS ($2.55), consensus ($2.84) TSVT 2seventy Bio $16.58 / -0.66 (-3.83%) 07/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations TSVT 2seventy Bio $16.58 / -0.66 (-3.83%) 04/29/22 Fourteen new option listings and one option delisting on April 29th
Recommendations	Karuna Therapeutics price target raised to $330 from $200 at Guggenheim » 07:51 08/12/22 08/12 07:51 08/12/22 07:51 KRTX Karuna Therapeutics $261.01 / +2.05 (+0.79%) Guggenheim analyst Yatin… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events KRTX Karuna Therapeutics $261.01 / +2.05 (+0.79%) 08/08/22 Zai Lab partner Karuna announces results from Phase 3 EMERGENT-2 trial 08/08/22 Karuna Therapeutics says Phase 3 EMERGENT-2 trial met primary endpoint KRTX Karuna Therapeutics $261.01 / +2.05 (+0.79%) 08/10/22 Wells Fargo Karuna Therapeutics price target raised to $264 from $186 at Wells Fargo 08/09/22 Mizuho Karuna Therapeutics price target raised to $276 from $190 at Mizuho 08/09/22 Citi Zai Lab price target raised to $199 from $193 at Citi 08/09/22 BofA Karuna Therapeutics price target raised to $261 from $160 at BofA KRTX Karuna Therapeutics $261.01 / +2.05 (+0.79%) 08/08/22 Karuna Therapeutics reports Q2 EPS ($2.17), consensus ($2.09) 05/05/22 Karuna Therapeutics reports Q1 EPS ($1.95), consensus ($2.11) 02/24/22 Karuna Therapeutics reports Q4 EPS (94c), consensus ($1.73) 10 Aug 10 Nov KRTX Karuna Therapeutics $261.01 / +2.05 (+0.79%) 08/08/22 What You Missed On Wall Street On Monday 08/08/22 What You Missed On Wall Street This Morning 08/08/22 Fly Intel: Pre-market Movers 07/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/15/22 2022 Biotech Summer Summit
Recommendations	SunOpta price target raised to $14 from $12 at Canaccord » 07:50 08/12/22 08/12 07:50 08/12/22 07:50 STKL SunOpta $10.73 / +1.815 (+20.36%) Canaccord analyst Bobby… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events STKL SunOpta $10.73 / +1.815 (+20.36%) 04/04/22 SunOpta unveils new headquarters and innovation center in Eden Prairie, Minn. STKL SunOpta $10.73 / +1.815 (+20.36%) 02/25/22 Canaccord SunOpta price target lowered to $12 from $15 at Canaccord 12/28/21 Lake Street Lake Street names 18 small cap best ideas for 2022 11/11/21 Canaccord SunOpta price target lowered to $15 from $20 at Canaccord 09/10/21 Cowen Cowen starts SunOpta at Outperform with $15 price target STKL SunOpta $10.73 / +1.815 (+20.36%) 08/10/22 SunOpta raises FY22 revenue view to $930M-$960M from $890M-$930M 08/10/22 SunOpta reports Q2 EPS 3c, consensus 0c 06/03/22 SunOpta sees FY25 revenue $1.3B 06/03/22 SunOpta backs FY23 revenue view $1.1B, consensus $1.27B STKL SunOpta $10.73 / +1.815 (+20.36%) 08/10/22 Fly Intel: After-Hours Movers 09/14/22 6th Annual Best Ideas Growth Conference: Big 6 09/07/22 SunOpta 10/17/22 SunOpta 10/18/22 SunOpta 10/19/22 SunOpta

Recommendations	Privia Health price target raised to $45 from $40 at Canaccord » 07:49 08/12/22 08/12 07:49 08/12/22 07:49 PRVA Privia Health $37.81 / +1.42 (+3.90%) Canaccord analyst Richard… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events PRVA Privia Health $37.81 / +1.42 (+3.90%) 03/31/22 Privia Health appoints Cocozza to board of directors 03/22/22 Privia Health CFO Jeff Sherman resigns PRVA Privia Health $37.81 / +1.42 (+3.90%) 07:41 Today Cowen Privia Health price target raised to $44 from $35 at Cowen 07/14/22 Truist Privia Health price target raised to $40 from $36 at Truist 06/29/22 Canaccord Privia Health price target raised to $40 from $29 at Canaccord 05/13/22 Canaccord Privia Health price target lowered to $29 from $44 at Canaccord PRVA Privia Health $37.81 / +1.42 (+3.90%) 08/11/22 Privia Health sees 2022 revenue at high end of $1.225B-$1.3B 08/11/22 Privia Health reports Q2 adjusted EPS 13c vs. 9c last year. 05/12/22 Privia Health sees FY22 revenue at the mid to high end of $1.225B-$1.3B range 05/12/22 Privia Health reports Q1 adjusted EPS 12c, consensus (4c) 19 Nov PRVA Privia Health $37.81 / +1.42 (+3.90%) 05/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/22/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/20/22 Privia Health 09/21/22 Privia Health
Recommendations	Pear Therapeutics price target lowered to $9 from $13 at Chardan » 07:48 08/12/22 08/12 07:48 08/12/22 07:48 PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) Chardan analyst Keay… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) 08/11/22 Pear Therapeutics reduced workforce on July 25 due to macro environment 08/10/22 Pear Therapeutics announces publication of insomnia analysis 08/08/22 Pear Therapeutics, SelectHealth announce reSET-O added as covered benefit 08/03/22 Pear, Cove Behavioral avail patients PDT reSET-O for opiod abuse treatment PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) 06/24/22 BTIG Pear Therapeutics price target lowered to $11 from $12 at BTIG 05/24/22 Cowen Pear Therapeutics revenues raised on strong Rx growth, says Cowen 05/17/22 Chardan Pear Therapeutics price target lowered to $13 from $16 at Chardan 05/17/22 Citi Pear Therapeutics price target raised to $11 from $10 at Citi PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) 08/11/22 Pear Therapeutics reports Q2 EPS 4c, consensus (25c) 05/16/22 Pear Therapeutics backs FY22 revenue view $22M, consensus $21.06M 05/16/22 Pear Therapeutics reports Q1 EPS (17c), consensus (24c) 03/28/22 Pear Therapeutics sees FY22 revenue $22M, consensus $21.79M PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) 08/11/22 Fly Intel: After-Hours Movers 05/16/22 Fly Intel: After-Hours Movers PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) 05/11/22 Eighteen new option listings on May 11th
Recommendations	Laird Superfood price target lowered to $5 from $6 at Canaccord » 07:46 08/12/22 08/12 07:46 08/12/22 07:46 LSF Laird Superfood $1.99 / -0.145 (-6.79%) Canaccord analyst Bobby… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings LSF Laird Superfood $1.99 / -0.145 (-6.79%) 05/18/22 Laird Superfood names Anya Hamill interim CFO 04/26/22 Laird Superfood launches Bright Cups pods 04/04/22 Laird Superfood names Andrew Judd as Chief Commercial Officer LSF Laird Superfood $1.99 / -0.145 (-6.79%) 05/13/22 Craig-Hallum Laird Superfood price target lowered to $6 from $12 at Craig-Hallum 03/09/22 Craig-Hallum Laird Superfood price target lowered to $12 from $20 at Craig-Hallum 03/09/22 Canaccord Laird Superfood price target lowered to $12 from $17 at Canaccord 02/01/22 Craig-Hallum Laird Superfood price target lowered to $20 from $40 at Craig-Hallum LSF Laird Superfood $1.99 / -0.145 (-6.79%) 08/10/22 Laird Superfood reports Q2 EPS (54c), consensus (68c) 05/12/22 Laird Superfood backs FY22 revenue view $41M-$44M, consensus $41.81M 05/12/22 Laird Superfood reports Q1 adjusted EPS (74c), consensus (71c) 03/08/22 Laird Superfood sees FY22 revenue $41M-$44M, consensus $48.05M
Recommendations	Solo Brands price target lowered to $11 from $14 at Credit Suisse » 07:46 08/12/22 08/12 07:46 08/12/22 07:46 DTC Solo Brands $5.98 / -0.01 (-0.17%) Credit Suisse analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options DTC Solo Brands $5.98 / -0.01 (-0.17%) 08/11/22 Solo Brands rises 14.7% 08/09/22 Solo Brands rises 14.2% 05/27/22 Solo Brands rises 19.5% 05/27/22 Solo Brands rises 13.2% DTC Solo Brands $5.98 / -0.01 (-0.17%) 08/02/22 Citi Solo Brands transferred with Buy rating at Citi 05/13/22 Citi Solo Brands price target lowered to $11 from $16 at Citi 03/30/22 Citi Solo Brands price target lowered to $16 from $20 at Citi 01/11/22 Citi Solo Brands upgraded to Buy from Neutral at Citi DTC Solo Brands $5.98 / -0.01 (-0.17%) 08/11/22 Solo Brands sees FY22 revenue growth in mid-20% range, consensus $548.76M 08/11/22 Solo Brands reports Q2 adjusted EPS 40c, consensus 28c 05/12/22 Solo Brands sees FY22 revenue $540M-$570M, consensus $556.7M 05/12/22 Solo Brands reports Q1 adjusted EPS 19c, consensus 8c 28 Oct DTC Solo Brands $5.98 / -0.01 (-0.17%) 05/21/22 Short Report: Bearish bets increase in meme names GameStop and Carvana 03/29/22 What You Missed On Wall Street On Tuesday 03/29/22 What You Missed On Wall Street This Morning 03/29/22 Fly Intel: Pre-market Movers DTC Solo Brands $5.98 / -0.01 (-0.17%) 04/20/22 Five new option listings and one option delisting on April 20th
Periodicals	Regulators raised doubts about Cheniere's turbines years ago, Reuters reports » 07:45 08/12/22 08/12 07:45 08/12/22 07:45 LNG Cheniere Energy $154.67 / +3.97 (+2.63%) U.S. regulators raised… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options LNG Cheniere Energy $154.67 / +3.97 (+2.63%) 07/26/22 Cheniere and PTT sign long-term LNG sale and purchase agreement 07/20/22 Cheniere Energy in long term LNG sale and purchase pact with PetroChina unit 06/23/22 Chart Industries receives FNTP for Cheniere's Corpus Christi LNG project 06/22/22 Cheniere Energy, Chevron sign long-term LNG sale and purchase agreements LNG Cheniere Energy $154.67 / +3.97 (+2.63%) 08/05/22 Mizuho Cheniere Energy price target raised to $167 from $159 at Mizuho 05/31/22 Wells Fargo Wells Fargo downgrades Cheniere Energy Partners to Underweight on valuation 05/23/22 RBC Capital Cheniere Energy price target raised to $178 from $151 at RBC Capital 05/12/22 JPMorgan Cheniere Energy price target raised to $192 from $183 at JPMorgan LNG Cheniere Energy $154.67 / +3.97 (+2.63%) 08/04/22 Cheniere Energy reports Q2 EPS $2.90, consensus $3.17 05/04/22 Cheniere Energy raises FY22 EBITDA view from $7B-$7.5B to $8.2B-$8.7B 05/04/22 Cheniere Energy reports Q1 EPS ($3.41), may not compare to consensus $3.53 02/24/22 Cheniere Energy reports Q4 EPS ($5.22), consensus $1.77 LNG Cheniere Energy $154.67 / +3.97 (+2.63%) 07/08/22 Cheniere asks White House to exempt it from pollution rule, Reuters says LNG Cheniere Energy $154.67 / +3.97 (+2.63%) 02/24/22 What You Missed On Wall Street On Thursday 02/24/22 What You Missed On Wall Street This Morning LNG Cheniere Energy $154.67 / +3.97 (+2.63%) 07/26/22 Cheniere Energy call volume above normal and directionally bullish 07/06/22 Cheniere Energy call volume above normal and directionally bullish
Downgrade	CS Disco downgraded to Hold at Canaccord as estimates get reset » 07:45 08/12/22 08/12 07:45 08/12/22 07:45 LAW CS Disco $28.96 / +0.39 (+1.37%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly LAW CS Disco $28.96 / +0.39 (+1.37%) 06/06/22 DISCO appoints Tom Furr as CMO 06/01/22 CS Disco falls -10.8% 04/28/22 DISCO appoints Jignasha Amin Grooms as CHRO LAW CS Disco $28.96 / +0.39 (+1.37%) 07:15 Today Stifel CS Disco price target lowered to $30 from $40 at Stifel 06:15 Today BofA CS Disco downgraded to Neutral from Buy at BofA 06:05 Today Canaccord CS Disco downgraded to Hold from Buy at Canaccord 05:40 Today Cowen Cowen cuts CS Disco to Market Perform as momentum hits 'big snag' LAW CS Disco $28.96 / +0.39 (+1.37%) 08/11/22 CS Disco cuts FY22 revenue view to $132M-$136M from $149M-$153M 08/11/22 CS Disco sees Q3 revenue $32M-$34M, consensus $38.29M 08/11/22 CS Disco reports Q2 adjusted (23c), consensus (27c) 05/12/22 CS Disco sees Q2 revenue $32M-$34M, consensus $34.02M 15 Sep LAW CS Disco $28.96 / +0.39 (+1.37%) 08/11/22 Fly Intel: After-Hours Movers 05/12/22 Fly Intel: After-Hours Movers
Recommendations	Illumina price target lowered to $380 from $450 at Canaccord » 07:44 08/12/22 08/12 07:44 08/12/22 07:44 ILMN Illumina $227.64 / +0.44 (+0.19%) Canaccord analyst Kyle… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options ILMN Illumina $227.64 / +0.44 (+0.19%) 08/11/22 Illumina cuts FY22 core Illumina revenue growth view to 3.5%-4.5% 08/11/22 Illumina drops 22% to $177 after Q2 results miss estimates, FY22 guidance cut 06/09/22 Illumina drops 6% to $210.00 after departure of CFO 06/09/22 Illumina CFO Sam Samad to depart, Joydeep Goswami named interim CFO ILMN Illumina $227.64 / +0.44 (+0.19%) 07:16 Today Stifel Illumina price target lowered to $300 from $480 at Stifel 06:59 Today Citi Illumina price target lowered to $200 from $220 at Citi 06:36 Today Baird Illumina price target lowered to $215 from $306 at Baird 08/11/22 Piper Sandler Illumina miss 'surprising' given backlog, says Piper Sandler ILMN Illumina $227.64 / +0.44 (+0.19%) 08/11/22 Illumina cuts FY22 adjusted EPS view to $2.75-$2.90 from $4.00-$4.20 08/11/22 Illumina reports Q2 adjusted EPS 57c, consensus 65c 08/11/22 Notable companies reporting after market close 05/05/22 Illumina sees FY22 adjusted EPS $4.00-$4.20, consensus $4.15 ILMN Illumina $227.64 / +0.44 (+0.19%) 07/27/22 Illumina's Grail deal likely to be blocked by EU regulators, Reuters reports 07/13/22 Illumina lost bid to block EU watchdog review of Grail deal, Bloomberg reports ILMN Illumina $227.64 / +0.44 (+0.19%) 08/11/22 Fly Intel: After-Hours Movers 07/13/22 What You Missed On Wall Street On Wednesday 07/13/22 What You Missed On Wall Street This Morning 06/10/22 What You Missed On Wall Street On Friday 09/10/22 ESMO Congress 2022 ILMN Illumina $227.64 / +0.44 (+0.19%) 08/11/22 Illumina options imply 6.5% move in share price post-earnings 06/13/22 Illumina put buyer realizes 25% same-day gains 05/18/22 Early notable gainers among liquid option names on May 18th
Recommendations	Six Flags price target lowered to $20 from $32 at Truist » 07:44 08/12/22 08/12 07:44 08/12/22 07:44 SIX Six Flags $21.12 / -4.685 (-18.16%) Truist analyst Michael… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 Six Flags falls -22.5% 08/11/22 Six Flags falls -21.5% 08/11/22 Six Flags falls -18.1% 08/11/22 Six Flags reports Q2 attendance 6.7M vs. 8.5M a year ago, down 22% SIX Six Flags $21.12 / -4.685 (-18.16%) 07:18 Today Stifel Six Flags price target lowered to $28 from $35 at Stifel 05:44 Today KeyBanc Six Flags downgraded to Sector Weight at KeyBanc after 'indefensible' Q2 08/11/22 KeyBanc Six Flags downgraded to Sector Weight from Overweight at KeyBanc 07/08/22 Citi Six Flags downgraded to Neutral from Buy at Citi SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 Six Flags reports Q2 EPS 53c, consensus $1.02 08/10/22 Notable companies reporting before tomorrow's open 08/10/22 Notable companies reporting before tomorrow's open 05/12/22 Six Flags reports Q1 EPS (76c), consensus ($1.04) SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 What You Missed On Wall Street On Thursday 08/11/22 What You Missed On Wall Street This Morning 08/11/22 Fly Intel: Pre-market Movers 07/21/22 Fly Intel: After-Hours Movers
Recommendations	Xos price target lowered to $5 from $11 at DA Davidson » 07:42 08/12/22 08/12 07:42 08/12/22 07:42 XOS Xos $1.99 / -0.09 (-4.33%) DA Davidson analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly XOS Xos $1.99 / -0.09 (-4.33%) 08/04/22 Xos makes initial deliver of battery-electric stepvans to Gabrielli Truck Sales 07/29/22 Xos secures purchase order from AUSEV 07/19/22 Xos delivers 73 units to customers in Q2 07/12/22 Xos secures purchase order for 10 stepvans from Zeem Solutions XOS Xos $1.99 / -0.09 (-4.33%) 07/15/22 Northland Sunworks and Sunnova could trade down on Manchin news, says Northland 06/03/22 Northland Xos initiated with an Outperform at Northland 12/08/21 BofA Xos initiated with an Underperform at BofA 12/02/21 Goldman Sachs Xos initiated with a Neutral at Goldman Sachs XOS Xos $1.99 / -0.09 (-4.33%) 08/11/22 Xos reports Q2 EPS (6c), consensus (14c) 05/05/22 Xos sees Q2 revenue $8M-$11M, consensus $9.12M 05/05/22 Xos reports Q1 EPS (13c), consensus (11c) 03/28/22 Xos reports Q4 EPS 7c, consensus (11c) XOS Xos $1.99 / -0.09 (-4.33%) 06/06/22 What You Missed This Week in EVs and Clean Energy 03/28/22 Fly Intel: After-Hours Movers
Recommendations	Privia Health price target raised to $44 from $35 at Cowen » 07:41 08/12/22 08/12 07:41 08/12/22 07:41 PRVA Privia Health $37.81 / +1.42 (+3.90%) Cowen analyst Gary Taylor… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events PRVA Privia Health $37.81 / +1.42 (+3.90%) 03/31/22 Privia Health appoints Cocozza to board of directors 03/22/22 Privia Health CFO Jeff Sherman resigns PRVA Privia Health $37.81 / +1.42 (+3.90%) 07/14/22 Truist Privia Health price target raised to $40 from $36 at Truist 06/29/22 Canaccord Privia Health price target raised to $40 from $29 at Canaccord 05/13/22 Canaccord Privia Health price target lowered to $29 from $44 at Canaccord 05/03/22 BofA BofA starts Privia Health at Buy as value-based care play PRVA Privia Health $37.81 / +1.42 (+3.90%) 08/11/22 Privia Health sees 2022 revenue at high end of $1.225B-$1.3B 08/11/22 Privia Health reports Q2 adjusted EPS 13c vs. 9c last year. 05/12/22 Privia Health sees FY22 revenue at the mid to high end of $1.225B-$1.3B range 05/12/22 Privia Health reports Q1 adjusted EPS 12c, consensus (4c) 19 Nov PRVA Privia Health $37.81 / +1.42 (+3.90%) 05/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/22/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/20/22 Privia Health 09/21/22 Privia Health

Recommendations	Sanofi may not be liable for any Zantac litigation damages, says JPMorgan » 07:40 08/12/22 08/12 07:40 08/12/22 07:40 SNY Sanofi $43.46 / -1.74 (-3.85%) , GSK GSK plc $35.75 / -2.57 (-6.71%) , HLN Haleon $6.29 / -0.22 (-3.38%) , PFE Pfizer $48.31 / -1.62 (-3.24%) JPMorgan analysts Richard… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SNY GSK HLN PFE SNY Sanofi $43.46 / -1.74 (-3.85%) 08/11/22 Sanofi says 'confident in its legal defenses' related to U.S. Zantac litigation 08/04/22 Sanofi announces strategic collaboration with Innovent Biologics 07/21/22 Innate Pharma announces Sanofi decision to progress IPH6401/SAR'514 07/18/22 Editas Medicine appoints Mei as SVP, CMO GSK GSK plc $35.75 / -2.57 (-6.71%) 08/11/22 Haleon says it is not a party to any Zantac claims 08/11/22 GSK says no new 'material developments' related to Zantac litigation 08/11/22 Sanofi says 'confident in its legal defenses' related to U.S. Zantac litigation 08/11/22 GSK plc falls -7.9% HLN Haleon $6.29 / -0.22 (-3.38%) 08/11/22 Haleon says it is not a party to any Zantac claims 08/11/22 GSK says no new 'material developments' related to Zantac litigation 07/18/22 GSK plc announces completion of demerger of Haleon PFE Pfizer $48.31 / -1.62 (-3.24%) 06:47 Today Pfizer reports 'positive' results from Phase 3 study of 20vPnC 08/11/22 Haleon says it is not a party to any Zantac claims 08/11/22 Sanofi says 'confident in its legal defenses' related to U.S. Zantac litigation 08/08/22 Pfizer, Valneva initiate Phase 3 study of Lyme disease vaccine candidate VLA15 SNY GSK HLN PFE SNY Sanofi $43.46 / -1.74 (-3.85%) 05:33 Today Deutsche Bank Sanofi upgraded to Hold from Sell at Deutsche Bank 08/11/22 JPMorgan Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan 08/11/22 Deutsche Bank Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank 08/09/22 UBS Sanofi downgraded to Neutral from Buy at UBS GSK GSK plc $35.75 / -2.57 (-6.71%) 08/11/22 JPMorgan Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan 08/11/22 Deutsche Bank Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank 08/09/22 Baird Mersana Therapeutics price target raised to $20 from $18 at Baird 08/08/22 UBS GSK plc price target lowered to 1,820 GBp from 1,860 GBp at UBS HLN Haleon $6.29 / -0.22 (-3.38%) 08/11/22 JPMorgan Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan 08/11/22 Deutsche Bank Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank 07/29/22 Deutsche Bank Haleon initiated with a Hold at Deutsche Bank 07/25/22 Goldman Sachs Haleon initiated with a Buy at Goldman Sachs (last week) PFE Pfizer $48.31 / -1.62 (-3.24%) 08/11/22 JPMorgan Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan 08/11/22 Deutsche Bank Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank 08/09/22 Wells Fargo Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo 08/08/22 Cantor Fitzgerald Global Blood downgraded to Neutral from Overweight at Cantor Fitzgerald SNY GSK PFE SNY Sanofi $43.46 / -1.74 (-3.85%) 07/28/22 Sanofi sees 2022 business EPS growing 15% at CER 07/28/22 Sanofi reports Q2 business EPS EUR 1.73, up 16.7% at CER 04/28/22 Sanofi still expects 2022 business EPS to grow low double-digit at CER 04/28/22 Sanofi reports Q1 business EPS EUR 1.94, up 16.1% at CER GSK GSK plc $35.75 / -2.57 (-6.71%) 07/27/22 GSK plc reports Q2 adjusted EPS 34.7p vs. 28.2p last year 04/27/22 GlaxoSmithKline reaffirms FY22 sales growth between 5%-7% at CER 04/27/22 GlaxoSmithKline reports Q1 adjusted EPS 32.8p vs. 22.9p last year 04/13/22 GlaxoSmithKline backs FY22 revenue view up 5%-7% at CER, consensus $47.34B PFE Pfizer $48.31 / -1.62 (-3.24%) 07/28/22 Pfizer raises FY22 adjusted EPS view to $6.30-$6.45 from $6.25-$6.45 07/28/22 Pfizer reports Q2 adjusted EPS $2.04, consensus $1.80 07/27/22 Notable companies reporting before tomorrow's open 07/27/22 Notable companies reporting before tomorrow's open SNY GSK HLN PFE SNY Sanofi $43.46 / -1.74 (-3.85%) 08/11/22 GSK, Sanofi weakness related to Zantac litigation worries, Bloomberg reports GSK GSK plc $35.75 / -2.57 (-6.71%) 08/11/22 GSK, Sanofi weakness related to Zantac litigation worries, Bloomberg reports 07/18/22 GSK CEO says split will help deal with 'perennial underperformance,' FT reports 06/27/22 GSK's Haleon chooses Citi, UBS as spinoff brokers, Bloomberg says 06/27/22 GSK's Haleon chooses Citi, UBS as spinoff brokers, Bloomberg says HLN Haleon $6.29 / -0.22 (-3.38%) 08/11/22 GSK, Sanofi weakness related to Zantac litigation worries, Bloomberg reports PFE Pfizer $48.31 / -1.62 (-3.24%) 08/05/22 Pfizer in advanced talks to buy Global Blood for about $5B, WSJ reports 08/05/22 Pfizer in talks to buy Global Blood Therapeutics for about $5B, WSJ says 07/18/22 GSK CEO says split will help deal with 'perennial underperformance,' FT reports 06/28/22 FDA panel recommends omicron update for COVID vaccine boosters, CNBC says SNY GSK HLN PFE SNY Sanofi $43.46 / -1.74 (-3.85%) 08/11/22 What You Missed On Wall Street On Thursday 08/11/22 Renewed Zantac litigation concerns sinking these big-cap drugmakers 08/11/22 What You Missed On Wall Street This Morning 06/24/22 What You Missed On Wall Street On Friday GSK GSK plc $35.75 / -2.57 (-6.71%) 08/11/22 What You Missed On Wall Street On Thursday 08/11/22 Renewed Zantac litigation concerns sinking these big-cap drugmakers 08/11/22 What You Missed On Wall Street This Morning 08/09/22 What You Missed On Wall Street On Tuesday HLN Haleon $6.29 / -0.22 (-3.38%) 08/11/22 Renewed Zantac litigation concerns sinking these big-cap drugmakers 08/11/22 What You Missed On Wall Street This Morning 07/29/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 07/18/22 What You Missed On Wall Street This Morning PFE Pfizer $48.31 / -1.62 (-3.24%) 08/11/22 Renewed Zantac litigation concerns sinking these big-cap drugmakers 08/08/22 What You Missed On Wall Street On Monday 08/08/22 What You Missed On Wall Street This Morning 08/08/22 Fly Intel: Pre-market Movers 09/10/22 ESMO Congress 2022 GSK HLN PFE GSK GSK plc $35.75 / -2.57 (-6.71%) 08/11/22 GSK plc (ADR) call volume above normal and directionally bullish 08/10/22 GSK plc (ADR) call volume above normal and directionally bullish 07/29/22 GSK plc (ADR) call volume above normal and directionally bullish 07/22/22 Two new option listings and one option delisting on July 22nd HLN Haleon $6.29 / -0.22 (-3.38%) 07/27/22 new option listings and one option delisting on July 27th PFE Pfizer $48.31 / -1.62 (-3.24%) 08/11/22 Pfizer call volume above normal and directionally bullish 07/28/22 Unusually active option classes on open July 28th 06/30/22 Early notable gainers among liquid option names on June 30th 05/20/22 Early notable gainers among liquid option names on May 20th
Recommendations	ForgeRock price target lowered to $25 from $28 at Cowen » 07:39 08/12/22 08/12 07:39 08/12/22 07:39 FORG ForgeRock $22.24 / -1.13 (-4.84%) Cowen analyst Shaul Eyal… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events FORG ForgeRock $22.24 / -1.13 (-4.84%) 08/11/22 ForgeRock reports Q2 ARR $201.6M, up 30% y/y 05/11/22 ForgeRock introduces ForgeRock Autonomous Access 03/02/22 ForgeRock falls -10.0% FORG ForgeRock $22.24 / -1.13 (-4.84%) 07/13/22 Piper Sandler ForgeRock price target raised to $25 from $24 at Piper Sandler 06/22/22 JPMorgan ForgeRock price target lowered to $30 from $36 at JPMorgan 05/12/22 Deutsche Bank ForgeRock price target lowered to $15 from $16 at Deutsche Bank 05/12/22 Mizuho ForgeRock price target lowered to $24 from $32 at Mizuho FORG ForgeRock $22.24 / -1.13 (-4.84%) 08/11/22 ForgeRock sees FY22 adjusted EPS (49c)-(44c), consensus (42c) 08/11/22 ForgeRock sees Q3 adjusted EPS (17c)-(13c), consensus (7c) 08/11/22 ForgeRock reports Q2 adjusted EPS (17c), consensus (21c) 05/11/22 ForgeRock cuts FY22 EPS view to (45c)-(41c) from (38c)-(34c), consensus (36c) 16 Sep FORG ForgeRock $22.24 / -1.13 (-4.84%) 08/11/22 Fly Intel: After-Hours Movers 02/26/22 Short Report: Avis Budget, VTEX short interest at multi-week highs 08/23/22 ForgeRock 08/28/22 ForgeRock
Recommendations	Cellebrite price target lowered to $10 from $13 at Cowen » 07:38 08/12/22 08/12 07:38 08/12/22 07:38 CLBT Cellebrite $5.28 / -0.4 (-7.04%) Cowen analyst Shaul Eyal… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly CLBT Cellebrite $5.28 / -0.4 (-7.04%) 07/05/22 Cellebrite and Chainalysis launch partnership 06/30/22 Cellebrite announces availability of Cellebrite Physcial Analyzer Ultra Series 05/05/22 Cellebrite announces upcoming release of Cellebrite Premium 04/06/22 Cellebrite announces national police force of EMEA expanded partnership CLBT Cellebrite $5.28 / -0.4 (-7.04%) 07:14 Today William Blair Cellebrite downgraded to Market Perform at William Blair after guidance cut 06:06 Today William Blair Cellebrite downgraded to Market Perform from Outperform at William Blair 05/16/22 Cowen Cellebrite price target lowered to $13 from $17 at Cowen 05/13/22 Deutsche Bank Cellebrite price target lowered to $10 from $11 at Deutsche Bank CLBT Cellebrite $5.28 / -0.4 (-7.04%) 08/11/22 Cellebrite reports Q2 adjusted EPS 0c, consensus 3c 08/11/22 Cellebrite lowers FY22 revenue to $270M-$285M from $285M-$300M 05/12/22 Cellebrite sees FY22 revenue $285M-$300M, consensus $292.06M 05/12/22 Cellebrite reports Q1 adjusted EPS 1c, consensus 2c CLBT Cellebrite $5.28 / -0.4 (-7.04%) 02/24/22 What You Missed On Wall Street On Thursday 02/24/22 What You Missed On Wall Street This Morning 02/24/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Recommendations	LegalZoom price target lowered to $19 from $24 at Credit Suisse » 07:38 08/12/22 08/12 07:38 08/12/22 07:38 LZ LegalZoom $11.11 / -0.175 (-1.55%) Credit Suisse analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly LZ LegalZoom $11.11 / -0.175 (-1.55%) 03/11/22 LegalZoom trading resumes 03/11/22 LegalZoom trading halted, volatility trading pause 03/10/22 LegalZoom board approves $150M share repurchase program 03/10/22 LegalZoom appoints Block CLO Sivan Whiteley to board of directors LZ LegalZoom $11.11 / -0.175 (-1.55%) 07/28/22 Morgan Stanley LegalZoom downgraded to Underweight on estimate risk at Morgan Stanley 07/28/22 Morgan Stanley LegalZoom downgraded to Underweight from Equal Weight at Morgan Stanley 07/14/22 Morgan Stanley LegalZoom price target lowered to $12 from $13 at Morgan Stanley 04/19/22 Citi LegalZoom assumed with Buy from Neutral at Citi LZ LegalZoom $11.11 / -0.175 (-1.55%) 08/11/22 LegalZoom cuts FY22 revenue view to $612M-$616M from $650-$660M 08/11/22 LegalZoom sees Q3 revenue $149M-$151M, consensus $171.21M 08/11/22 LegalZoom reports Q2 EPS 5c, consensus 2c 05/12/22 LegalZoom sees Q2 revenue $162M-$164M, consensus $165.08M LZ LegalZoom $11.11 / -0.175 (-1.55%) 08/11/22 Fly Intel: After-Hours Movers 03/11/22 What You Missed On Wall Street On Friday 03/11/22 What You Missed On Wall Street This Morning 03/10/22 Fly Intel: After-Hours Movers
Recommendations	Rockley Photonics price target lowered to $14 from $21 at Cowen » 07:37 08/12/22 08/12 07:37 08/12/22 07:37 RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) Cowen analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 08/11/22 Rockley Photonics sees FY22 core product revenue $5M-$10M 08/09/22 Rockley Photonics gets first commercial order for Rockley Bioptx band 07/26/22 Rockley Photonics announces strategic partnership with contract research group 06/16/22 Rockley customer begins evaluation program using its sensing technology RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 06:37 Today Baird Rockley Photonics downgraded to Neutral from Outperform at Baird 06/08/22 Baird to hold a conference 06/07/22 Baird to hold a conference 05/13/22 Needham Rockley Photonics price target lowered to $4 from $8 at Needham RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 08/11/22 Rockley Photonics reports Q2 adjusted EPS (82c), consensus (25c) 06/15/22 Rockley Photonics affirms FY22 revenue guidance 05/12/22 Rockley Photonics reports Q1 adjusted EPS (28c), consensus (25c) 03/08/22 Rockley Photonics sees FY22 revenue $20M-$30M, consensus $24.87M RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 04/22/22 Rockley Photonics falls after Iceberg Research reveals short position 04/22/22 Iceberg Research announces short position in Rockley Photonics RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 04/22/22 What You Missed On Wall Street On Friday 04/22/22 What You Missed On Wall Street This Morning 03/08/22 Fly Intel: After-Hours Movers RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 06/22/22 Largest borrow rate increases among liquid names 05/12/22 Rockley Photonics Holdings options imply 14.2% move in share price post-earnings 03/08/22 Rockley Photonics Holdings options imply 13.6% move in share price post-earnings

Events

Earnings calls, analyst events, roadshows and more

Today at 08:30

Import Prices Y/Y: July 2022 Government Event
Today at 08:30

Export Prices M/M: July 2022 Government Event
Today at 08:30

Export Prices Y/Y: July 2022 Government Event
Today at 08:30

Import Prices M/M: July 2022 Government Event
PLXP
Today at 08:30

PLx Pharma - PLXP Conference Calls
RPID
Today at 08:30

Rapid Micro Biosystems - RPID Conference Calls
FLO
Today at 08:30

Flowers Foods - FLO Conference Calls
HOFV
Today at 08:30

Hall of Fame Resort & Entertainment - HOFV Conference Calls
KINS
Today at 08:30

Kingstone Companies - KINS Conference Calls
RGF
Today at 08:30

Real Good Food - RGF Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	AYTU X AYTU Aytu BioPharma Spot Secondary Managers: Cantor Fitzgerald & Canaccord Priced at: $0.43 21.5M Shares BRBR X BRBR BellRing Brands Spot Secondary Managers: JPMorgan, Barclays, Citi, Goldman Sachs & Morgan Stanley Priced at: $23.50 14.8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDNA X MDNA Medicenna Therapeutics Spot Secondary Managers: Guggenheim, Bloom Burton Securities Priced at: $1.50 13.333M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NUZE X NUZE NuZee Spot Secondary Managers: Maxim Priced at: $0.82 4.2M Shares PFLT X PFLT PennantPark Floating Rate Spot Secondary Managers: Morgan Stanley, Goldman Sachs, JPMorgan, Keefe Bruyette, RBC Capital & Truist Priced at: $12.40 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan, Jefferies Priced at: $215.00 3.49M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MIRM X MIRM Mirum Pharmaceuticals Spot Secondary Managers: JPMorgan, SVB Securities & Evercore ISI, Raymond James Priced at: $23.00 3.48M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TDW X TDW Tidewater Spot Secondary Managers: Morgan Stanley Priced at: $17.85 3.52M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	ATNX X ATNX Athenex Secondary Managers: SVB Securities Priced at: $.75 35.3M Shares CINC X CINC CinCor Pharma Secondary Managers: Goldman Sachs, Morgan Stanley, Jefferies & Piper Sandler Priced at: $30.00 7.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EVTC X EVTC Evertec Secondary Managers: JPMorgan Priced at: $32.00 6.26M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LXU X LXU LSB Industries Secondary Managers: Goldman Sachs & UBS, Deutsche Bank, Jefferies, Piper Sandler, RBC Capital, BNP Paribas, Stifel Priced at: $13.00 13.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SOVO X SOVO Sovos Brands Secondary Managers: JPMorgan & Goldman Sachs, BofA, Credit Suisse, Barclays, UBS, Cowen, Piper Sandler, Stifel, William Blair, Telsey Advisory, Drexel Hamilton, Loop Capital Priced at: $14.00 8.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRNA X VRNA Verona Pharma Secondary Managers: Jefferies, Piper Sandler & Truist Priced at: $10.50 12.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNL X BNL Broadstone Net Lease Spot Secondary Managers: Goldman Sachs, BMO Capital, JPMorgan & Truist Priced at: $21.35 13M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KIDS X KIDS OrthoPediatrics Spot Secondary Managers: Piper Sandler & Stifel Priced at: $55.00 750K Shares MAIN X MAIN Main Street Spot Secondary Managers: RBC Capital, UBS & Wells Fargo Priced at: $42.85 1.17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	FRZA X FRZA Forza X1 IPO Managers: ThinkEquity Priced at: $5.00 3M Shares REBN X REBN Reborn Coffee IPO Managers: EF Hutton Priced at: $5.00 1.44M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TGL X TGL Treasure Global IPO Managers: EF Hutton Priced at: $4.00 2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERE X CERE Cerevel Therapeutics Secondary Managers: Morgan Stanley, Goldman Sachs, Jefferies & Evercore ISI, Loop Capital, Seibert Williams Priced at: $35.00 7.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INAB X INAB In8bio Secondary Managers: H.C. Wainwright Priced at: $1.90 5.39M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PTLO X PTLO Portillo's Secondary Managers: Jefferies & Morgan Stanley, BofA, Piper Sandler Priced at: $23.75 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INSP X INSP Inspire Medical Spot Secondary Managers: Goldman Sachs Priced at: $215.00 1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	BIAF X BIAF Bioaffinity Technologies IPO Managers: WallachBeth $6.00-6.25 1.285M Shares
Wed	No deals
Thurs	RANI X RANI Rani Therapeutics Secondary Managers: BofA, Cantor Fitzgerald & UBS, BTIG, H.C. Wainwright $ Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERT X CERT Certara Spot Secondary Managers: Morgan Stanley $17.75-18.50 7M Shares
Fri	No deals

View All Syndicate Announcements »

Oppenheimer says U.S. financial institutions 'dramatically undervalued'

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access